Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Buy
69
CPRX Quote, Financials, Valuation and Earnings
Last price:
$23.52
Seasonality move
:
29.47%
Day range:
$23.25 - $23.83
52-week range:
$14.75 - $26.58
Dividend yield:
0%
P/E ratio:
14.99x
P/S ratio:
5.54x
P/B ratio:
3.61x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
53.49%
Market cap:
$2.9B
Revenue:
$491.7M
EPS (TTM):
$1.57
Analysts' Opinion
-
Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $34.29, Catalyst Pharmaceuticals has an estimated upside of 45.71% from its current price of $23.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $31.00 representing 100% downside risk from its current price of $23.53.
Fair Value
-
According to the consensus of 6 analysts, Catalyst Pharmaceuticals has 45.71% upside to fair value with a price target of $34.29 per share.
CPRX vs. S&P 500
-
Over the past 5 trading days, Catalyst Pharmaceuticals has underperformed the S&P 500 by -8.69% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Catalyst Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Catalyst Pharmaceuticals has grown year-over-year revenues for 18 quarters straight. In the most recent quarter Catalyst Pharmaceuticals reported revenues of $141.4M.
Earnings Growth
-
Catalyst Pharmaceuticals has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Catalyst Pharmaceuticals reported earnings per share of $0.45.
Enterprise value:
2.3B
EV / Invested capital:
--
Price / LTM sales:
5.54x
EV / EBIT:
9.90x
EV / Revenue:
4.28x
PEG ratio (5yr expected):
0.08x
EV / Free cash flow:
8.55x
Price / Operating cash flow:
11.05x
Enterprise value / EBITDA:
8.51x
Gross Profit (TTM):
$460.4M
Return On Assets:
25.4%
Net Income Margin (TTM):
36.91%
Return On Equity:
29.43%
Return On Invested Capital:
29.43%
Operating Margin:
44.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $256.5M | $411.3M | $534.6M | $98.5M | $141.4M | |
| Gross Profit | $218M | $356.8M | $460.4M | $86M | $123.5M | |
| Operating Income | $120.1M | $78.3M | $231.4M | $27.1M | $63.4M | |
| EBITDA | $127.9M | $114M | $269.2M | $36.6M | $72.8M | |
| Diluted EPS | $0.88 | $0.54 | $1.57 | $0.19 | $0.45 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $161.5M | $221.2M | $198.9M | $404.6M | $685.7M | |
| Total Assets | $197.2M | $247M | $407.2M | $646.7M | $908.9M | |
| Current Liabilities | $14.4M | $22.9M | $56.7M | $79.6M | $111.6M | |
| Total Liabilities | $18.6M | $26.8M | $73.6M | $85.3M | $114.6M | |
| Total Equity | $178.7M | $220.2M | $333.7M | $561.4M | $794.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $119.6M | $163.5M | $267.9M | $31.9M | $60M | |
| Cash From Investing | -$153.2M | -$131.3M | -$357K | -$199K | -- | |
| Cash From Financing | $3.4M | $130M | $2.7M | $141M | $3.1M | |
| Free Cash Flow | $119.5M | $81.6M | $267.9M | $31.7M | $60M | |
CPRX
Sector
Market Cap
$2.9B
$33.4M
Price % of 52-Week High
88.53%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
53.49%
-37.4%
Beta (5-Year)
0.721
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$25.24
200-day SMA
Buy
Level
$22.24
Bollinger Bands (100)
Buy
Level
22.04 - 24.6
Chaikin Money Flow
Buy
Level
9.9M
20-day SMA
Sell
Level
$24.86
Relative Strength Index (RSI14)
Sell
Level
40.75
ADX Line
Sell
Level
17.02
Williams %R
Buy
Level
-91.5916
50-day SMA
Sell
Level
$23.84
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.7402)
Buy
CA Score
(Annual)
Level (2.7381)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-6.8773)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Stock Forecast FAQ
In the current month, CPRX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPRX average analyst price target in the past 3 months is $34.29.
-
Where Will Catalyst Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Catalyst Pharmaceuticals share price will rise to $34.29 per share over the next 12 months.
-
What Do Analysts Say About Catalyst Pharmaceuticals?
Analysts are divided on their view about Catalyst Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Catalyst Pharmaceuticals is a Sell and believe this share price will drop from its current level to $31.00.
-
What Is Catalyst Pharmaceuticals's Price Target?
The price target for Catalyst Pharmaceuticals over the next 1-year time period is forecast to be $34.29 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Catalyst Pharmaceuticals is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CPRX?
You can purchase shares of Catalyst Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Catalyst Pharmaceuticals shares.
-
What Is The Catalyst Pharmaceuticals Share Price Today?
Catalyst Pharmaceuticals was last trading at $23.52 per share. This represents the most recent stock quote for Catalyst Pharmaceuticals. Yesterday, Catalyst Pharmaceuticals closed at $23.53 per share.
-
How To Buy Catalyst Pharmaceuticals Stock Online?
In order to purchase Catalyst Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
